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Introduction
Acute lymphoblastic leukemia (ALL) is the most common
cancer of childhood.1 The prognosis of this disease has
improved greatly over the last 40 years and cure rates cur-
rently exceed 80%.2 The 8-year event-free survival and over-
all survival rates in treatment protocol 58951 of the
Children’s Leukemia Group (CLG) of the European
Organization for Research and Treatment of Cancer
(EORTC) reached 81% and 89%, respectively.3-5
Improvements in diagnosis, novel insights into disease biolo-
gy and, most importantly, better risk stratification, have con-
tributed enormously to this success.5,6
In current treatment protocols, high-risk ALL is defined by
hypodiploidy/near-hypodiploidy, presence of the chromoso-
mal translocation t(9;22)(BCR–ABL1), mixed-lineage
leukemia (MLL) gene rearrangements, poor pre-phase
response, absence of complete remission after induction
treatment or high levels of minimal residual disease.
Although the relative percentage of hematologic relapses in
ALL is clearly greater in high-risk patients, the absolute num-
ber of disease recurrences is actually higher in non-high-risk
patients, who account for up to 75% of cases of pediatric
ALL and who predominantly have ALL of B-cell lineage.7
Identification of additional prognostic markers that could be
used for risk stratification in non-high-risk B-cell precursor
(BCP)-ALL is, therefore, of utmost importance. 
Recent genome-wide screening approaches have identified
©2015 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2015.126953
The online version of this article has a Supplementary Appendix.
Manuscript received on March 9, 2015. Manuscript accepted on June 23, 2015.
Correspondence: barbara.demoerloose@uzgent.be
DNA copy number analysis has been instrumental for the identification of genetic alterations in B-cell precursor
acute lymphoblastic leukemia. Notably, some of these genetic defects have been associated with poor treatment
outcome and might be relevant for future risk stratification. In this study, we characterized recurrent deletions of
CD200 and BTLA genes, mediated by recombination-activating genes, and used breakpoint-specific polymerase
chain reaction assay to screen a cohort of 1154 cases of B-cell precursor acute lymphoblastic leukemia uniformly
treated according to the EORTC-CLG 58951 protocol. CD200/BTLA deletions were identified in 56 of the patients
(4.8%) and were associated with an inferior 8-year event free survival in this treatment protocol [70.2% ± 1.2%
for patients with deletions versus 83.5% ± 6.4% for non-deleted cases (hazard ratio 2.02; 95% confidence interval
1.23-3.32; P=0.005)]. Genetically, CD200/BTLA deletions were strongly associated with ETV6-RUNX1-positive
leukemias (P<0.0001), but were also identified in patients who did not have any genetic abnormality that is cur-
rently used for risk stratification. Within the latter population of patients, the presence of CD200/BTLA deletions
was associated with inferior event-free survival and overall survival. Moreover, the multivariate Cox model indi-
cated that these deletions had independent prognostic impact on event-free survival when adjusting for conven-
tional risk criteria. All together, these findings further underscore the rationale for copy number profiling as an
important tool for risk stratification in human B-cell precursor acute lymphoblastic leukemia. This trial was regis-
tered at www.ClinicalTrials.gov as #NCT00003728.
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ABSTRACT
several recurring genetic alterations in BCP-ALL, some of
which show prognostic relevance.8 These cooperative
somatic lesions include copy number alterations and
mutations targeting tumor suppressors, cell-cycle and
apoptotic regulators, drug-receptor genes and lymphoid-
signaling molecules.9,10 For example, more than 40% of
BCP-ALL patients harbor mutations in critical transcrip-
tional regulators of B lymphoid development including
Paired Box 5 (PAX5), Early B-Cell Factor 1 (EBF1) and
IKAROS Family Zinc Finger 1 (IKZF1). Notably, IKZF1
deletions have convincingly been associated with poor
prognosis in both BCR–ABL1-positive as well as unselect-
ed BCP-ALL cohorts of patients.11,12 Of note, two inde-
pendent studies recently showed that intragenic ERG
deletions attenuate the unfavorable impact of IKZF1 dele-
tions, suggesting that full genomic profiling is important
in studying prognostic factors in BCP-ALL.3,13
In this study, we performed high-resolution copy num-
ber analysis on leukemic specimens from 70 average-risk
pediatric BCP-ALL patients treated according to the
EORTC-CLG 58951 protocol. In this initial cohort, previ-
ously reported genomic deletions encompassing the B
and T lymphocyte attenuator (BTLA; also called CD272)
and CD200 genes2,14-18 were associated with a high inci-
dence of hematologic relapse. Subsequently, we extended
the cohort to 1154 BCP-ALL patients treated on the
EORTC-CLG 58951 protocol to evaluate the biological
and clinical relevance of CD200/BTLA deletions in BCP-
ALL.
Methods
Full details of the methods are provided in the Online
Supplementary Methods.
Patients
Patients under 18 years of age with previously untreated ALL
were enrolled in the EORTC-CLG 58951 trial between December
1998 and July 2008. This protocol was approved by the EORTC
Protocol Review Committee and by the local institutional ethical
committees in each participating center and is registered at
ClinicalTrials.gov (#NCT00003728). After obtaining informed
consent from patients or their legal guardians according to the dec-
laration of Helsinki, bone marrow and blood samples were taken
at diagnosis, before the start of treatment, and stored for future
research purposes. All analyses were performed on cryopreserved
leukemic cells.
Diagnostics, risk group assignment and treatment were per-
formed according to the EORTC-CLG 58951 protocol. This proto-
col is based on a Berlin-Frankfurt-Munster (BFM)-backbone with
four-drug induction, consolidation, central nervous system pro-
phylaxis without cranial irradiation, re-induction/late intensifica-
tion and maintenance, and includes three randomized compar-
isons as described previously.5,19
Array comparative genome hybridization 
The DNA of samples and cell lines was profiled on the 180K
custom-designed oligonucleotide array platform. In brief, genomic
DNA from patients and controls was labeled using random prime
labeling with Cy3 and Cy5 dyes (Perkin Elmer, Waltham, MA,
USA). Next, hybridization was performed according to the manu-
facturer’s instructions (Agilent Technologies) and then the data
were analyzed using the arrayCGHbase tool, developed in-
house.20 In addition, a custom focused 8*15K oligonucleotide array
(Agilent Technologies, Santa Clara, CA, USA) was designed for
fine-mapping the deletion encompassing BTLA and CD200. 
High throughput screening for CD200/BTLA deletions  
Primers flanking the junctions were designed based on break-
point sequences, using Primer3Plus software and included: F1: 5’-
TTTCCGGAGTCTCAGAGAGGT -3’, F2: 5’-
AGGCTTTGCTTCGTCTTCTG-3’, and R(6-FAM-labeled): 5’-
TTAAAGACGGCTGCTCTTCC -3’.
Fifty nanograms of DNA were amplified using standard poly-
merase chain reaction (PCR) procedures, with 1.5 mM MgCl2 and
an annealing temperature of 60°C. Fluorescent PCR products were
analyzed using the ABI 3130 analyzer and GeneMapper® software
(Applied Biosystems).  
Statistical analysis
Event-free survival was calculated from the date of diagnosis to
the date of last follow up or the first event (no complete remission,
relapse or death). Disease-free survival was calculated from the date
of complete remission to the date of last follow-up or the first event
(relapse or death). All patients alive and in first complete remission
were censored at their last follow-up. Overall survival was calculated
from the date of diagnosis until the date of death. Patients still alive
were censored at their last follow-up. Survival rates were calculated
using the Kaplan-Meier technique, and standard errors of estimates
were obtained from the Greenwood formula. Differences between
Kaplan-Meier curves were tested for statistical significance using the
two-tailed log-rank test. The Cox proportional hazard model was
used to obtain the estimate and the 95% confidence interval (CI) of
the hazard ratio (HR) of the instantaneous event rate in one group
versus another, as specified by a given variable. All analyses were
based on the intent-to-treat principle. The relationship between
presence/absence of CD200/BTLA deletions and categorical vari-
ables was tested for significance using the Fisher test, and for contin-
uous variables (e.g. age) using the Wilcoxon test. 
Results
Recurrent CD200/BTLA deletions in average-risk 
precursor-B cell acute lymphoblastic leukemia 
Copy number profiling was performed on leukemic
blasts from 70 children with average-risk BCP-ALL treated
with the EORTC-CLG 58951 protocol. Array comparative
genome hybridization (CGH) analysis revealed a recurrent
deletion of a genomic region (~164kb) on the long arm of
chromosome 3 (3q13.2) in seven out of 70 (10%) patients;
the deletion  encompassed the lymphoid signaling mole-
cules BTLA (CD272) and CD200 genes. In this series, five
out of seven deletions were mono-allelic for both genes
(Figure 1A), whereas the two other samples showed
mono-allelic loss of CD200 in combination with bi-allelic
deletion of BTLA (Figure 1B). Furthermore, copy number
profiling in human BCP-ALL cell lines revealed similar bi-
allelic CD200/BTLA deletions in the ETV6-RUNX1-posi-
tive REH cell line (Figure 1C).
To evaluate somatic mutations as an alternative mecha-
nism of BTLA or CD200 inactivation in pediatric BCP-
ALL, we performed sequencing of all coding exons of
BTLA and CD200 in the same panel of 70 average-risk
pediatric BCP-ALL patients (Online Supplementary Table
S1). This analysis failed to identify somatic loss-of-func-
tion mutations targeting BTLA or CD200 (Online
Supplementary Table S2).
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Next, we evaluated the functional consequences of
CD200/BTLA deletions on the expression levels of both
lymphoid signaling factors. First, quantitative reverse tran-
scriptase PCR in a panel of BCP-ALL cell lines showed that
CD200/BTLA deletions completely abolished CD200 and
BTLA expression in the REH cell line, whereas their
expression levels were variable in the non-deleted cell
lines (Figure 1D). In addition, these results were confirmed
at the protein level by flow cytometry. Notably, CD200
expression was usually strong, whereas BTLA was virtual-
ly absent across the panel of BCP-ALL cell lines (Figure
1E). Finally, similar analyses were performed on leukemic
lymphoblasts from 23 patients with primary BCP-ALL,
including three who harbored mono-allelic CD200/BTLA
deletions. Analysis of CD19+ CD3- leukemic lymphoblasts
revealed low levels of BTLA in all BCP-ALL samples with-
out significant differences in BTLA expression between
deleted (mean fluorescence intensity, MFI: 198±109) and
non-deleted leukemias (MFI: 378±74). In contrast, CD200
protein expression was more prominent in all primary
BCP-ALL blasts with a clear decrease in MFI in deleted
BCP-ALL cases (MFI in deleted cases: 2830±1110 versus
MFI in non-deleted cases:  6730±980)  (Figure 1F) (Online
Supplementary Table S3). 
Genomic breakpoints of CD200/BTLA deletions 
in precursor-B cell acute lymphoblastic leukemia 
To map the exact genomic breakpoints of CD200/BTLA
deletions in BCP-ALL, we developed a custom array with
high-density probe coverage at chromosomal band 3q13.2
surrounding the CD200 and BTLA genes. Notably, exact
recombination-activating genes (RAG) recognition
sequences were identified at both proximal and distal
breakpoints with some random nucleotides inserted at the
junctions, suggesting that aberrant activity of RAG
enzymes might act as the driving mechanism for
CD200/BTLA deletions in pediatric B-cell precursor ALL
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Figure 1. Characterization of focal deletions of CD200/BTLA. CGH log2 copy number ratio data shown as representation for (A) a mono-allelic
deletion of CD200 and CD272 (BTLA) genes, (B) a mono-allelic deletion of CD200 gene and a bi-allelic deletion of CD272 (BTLA) in two dif-
ferent BCP-ALL cases and (C) a bi-allelic deletion of CD200 and CD272 (BTLA) in the REH cell line. (D) Quantitative reverse transcriptase-PCR
analysis in eight B-ALL cell lines confirmed that deletion of CD200 and CD272 (BTLA) abolishes their expression in the REH cell line. The
expression profiles of CD200 and CD272 (BTLA) are shown on a logarithmic scale in (E) three B-ALL cell lines and (F) BCP-ALL patients. The
top panel shows the expression level of CD200 and CD272 (BTLA) in one wild-type and one deleted case and the box plots in the lower panel
represent the mean fluorescence intensity of CD200 and CD272 (BTLA) in three deleted and 20 non-deleted BCP-ALL cases. Asterisks indicate
samples used to generate the top panels.
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CD200/BTLA deletions in BCP-ALL (Figure 2A).
Next, we developed primers near the breakpoint cluster
regions as a strategy to identify the exact genomic break-
point sequences of CD200/BTLA deletions by PCR analy-
sis and Sanger sequencing (Figure 2B). Analysis of five
cases of CD200/BTLA deletion-positive BCP-ALL and the
REH cell line showed that the genomic breakpoints of the
CD200/BTLA deletions were conserved with minimal dif-
ferences between CD200/BTLA deletions from different
BCP-ALL patients (Figure 2C). 
Clinical and biological features of CD200/BTLA-deleted
precursor-B cell acute lymphoblastic leukemia
In the initial cohort, CD200/BTLA deletions were associ-
ated with a high incidence of hematologic relapse (4/7),
whereas only eight out of 63 patients without a
CD200/BTLA deletion relapsed. To evaluate the clinical and
biological features of CD200/BTLA deletion-positive BCP-
ALL, we extended the cohort to 1154 BCP-ALL patients
treated according to the EORTC-CLG 58951 protocol and
screened for the presence of CD200/BTLA deletions. To this
end, we optimized a breakpoint-specific fluorescent PCR
assay based on the primer combinations used for the
genomic breakpoint characterization (Figure 2B).
CD200/BTLA deletions were detected in 56 out of 1154
patients (4.8%); the patients’ clinical and biological fea-
tures according to CD200/BTLA status are presented in
Table 1. No significant differences were observed between
patients with and without CD200/BTLA deletions.
However, whereas pre-phase response was similar in
patients with and without deletions, a higher proportion
of patients with minimal residual disease levels ≥10-2 after
F. Ghazavi et al.
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Figure 2. Genomic breakpoints
of CD200/BTLA deletions in
BCP-ALL patients. (A) Custom
oligo array with high-density
probe coverage at ch3q13.2,
the RAG recognition sequences
were identified within the delet-
ed region. Each small vertical
blue line indicates an exon. The
thicker the line, the larger the
exon. (B) Schematic represen-
tation of the CD200 and BTLA
genes with locations of primers
used for breakpoint-specific
multiplex fluorescent PCR
assay. Boxes represent genes,
the arrows represent the
primers and the star repre-
sents the fluorescent-labeled
primer. Patients with mono-
allelic deletion of both genes
show both bands of F1/R and
F2/R, patients with mono-allel-
ic deletion of CD200 and bi-
allelic deletion of BTLA show
only the band of F1/R, patients
with no deletion show only the
band of F2/R. (C) Alignment of
breakpoint sequences of five
cases of CD200/BTLA deletion-
positive BCP-ALL (n.1-5) and
the REH cell line (n.6) with wild-
type sequence showed that the
genomic breakpoints of the
CD200/BTLA deletions were
conserved. 
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induction was found in the CD200/BTLA-deleted group
(7.1% versus 2.65%; P=0.54, Table 1). Diagnostic samples
were not available from 98 BCP-ALL patients in the 58951
protocol. The characteristics of these children did not dif-
fer from those of the tested cohort (Online Supplementary
Table S4).
The distribution of CD200/BTLA non-deleted versus
deleted cases among well-known genetic aberrations and
different genetic risk groups is shown in Table 2. The def-
inition of genetic risk groups is based on internationally
accepted prognostic associations of the main classifying
genetic lesions. The good-prognosis genetic group
includes patients with high hyperdiploidy, ETV6–RUNX1
translocation or ERG deletion,3 whereas the poor-progno-
sis genetic group consists of patients with BCR-ABL
translocation, near-haploidy, low hypodiploidy, MLL
translocations or iAMP21. The remaining patients (TCF3-
PBX1 and B-other) are classified in the intermediate-prog-
nosis genetic group. 
The highest frequency of CD200/BTLA deletions was
seen in the poor-prognosis genetic group (8/79=10.1%).
The deletions were detected in 5.5% (39/705) and 2.4%
(9/370) of the good-prognosis and intermediate-prognosis
genetic groups, respectively. The highest number of
CD200/BTLA-deleted cases (39/56, 69.6%) was found in
the good-prognosis genetic group with a striking associa-
tion of CD200/BTLA deletions with the presence of the
ETV6/RUNX1 fusion gene (34/282, P<0.0001).
Significantly fewer cases of CD200/BTLA deletions were
seen among high-hyperdiploid patients (4/386, P=0.0001)
(Table 2).
Prognostic relevance of CD200/BTLA deletions 
in precursor-B cell acute lymphoblastic leukemia
Survival analyses were performed to evaluate the prog-
nostic relevance of CD200/BTLA deletions in the whole
BCP-ALL cohort. Figure 3 shows the event-free survival,
disease-free survival and overall survival curves of the
patients according to CD200/BTLA status, with a median
follow-up of 6.9 years. The 8-year event-free survival rate
was 83.5% (95% CI 80.9-85.7) for patients without
CD200/BTLA deletions whereas it was only 70.2% (95%
CI 55.8-80.8) in the group with CD200/BTLA deletions
(HR 2.02; 95% CI 1.23-3.32; P=0.005). There were 17
events in the group of 56 patients with CD200/BTLA dele-
tions whereas 168 events were seen in the 1098 patients
without CD200/BTLA deletions. Survival analysis from
complete remission showed that the CD200/BTLA dele-
tions were significantly associated with inferior 8-year dis-
ease-free survival within the whole group of patients
(72.8% versus 84.4%; HR 1.92; 95% CI 1.13-3.26;
P=0.014). In contrast, no significant difference was
observed in the 8-year overall survival rate between BCP-
ALL patients with and without CD200/BTLA deletions
(91.4% versus 87%; HR 1.57; 95% CI 0.73-3.4; P=0.247).
Event status and relapse type for the groups of patients
with and without deletions are summarized in Table 3. 
Eight-year event-free survival and overall survival rates
were significantly different in previously defined good-
prognosis, intermediate-prognosis and poor-prognosis
genetic groups (Online Supplementary Figure S1A). The
occurrence of CD200/BTLA deletions did not influence
event-free survival rates of the patients in the good-prog-
nosis genetic group (HR 1.38; 99% CI 0.41-4.57; P=0.49)
nor did it influence overall survival rate (HR 0.65; 99% CI
0.05-8.96; P=0.66) (Online Supplementary Figure S1B). In the
poor-prognosis genetic group, patients with CD200/BTLA
CD200/BTLA deletions in pediatric B-cell precursor ALL
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Table 1. Clinical and biological features of BCP-ALL patients according
to CD200/BTLA deletions status.
                                      Not deleted (n=1098)   Deleted (n=56)  P value
Characteristic                             N. (%)                      N. (%)               
Gender
     Male                                            587 (53.5)                     30 (53.6)                1
     Female                                       511 (46.5)                     26 (46.4)                
Age at diagnosis (years):                                                                             0.8
    <1                                                   3 (0.3)                          0 (0)                   
    1 – < 10                                     880 (80.2)                    44 (78.6)               
    ≥10                                              215 (19.6)                    12 (21.4)               
WBC count (x109/L):                                                                                         0.5
     <10                                              617 (56.2)                     28 (50.0)
     10-<25                                        214 (19.5)                     15 (26.8)
     25-<100                                      209 (19.0)                      8 (14.3)
     ≥100                                              58 (5.3)                         5 (8.9)
NCI risk group:                                                                                              0.55 
    Standard risk                            772 (70.3)                    37 (66.1)               
    High risk                                    326 (29.7)                    19 (33.9)               
Pre-phase response:                                                                                       0.88
     <1x109/L                                    1027 (93.5)                    53 (94.6)
     ≥1x109/L                                        71 (6.5)                         3 (5.4)
MRD after induction:                                                                                   0.54
    ≥10-2                                              29 (2.6)                        4 (7.1)                 
    10-2 to 10-3                                     64 (5.8)                        4 (7.1) 
     Undetectable                           877 (79.9)                    41 (73.2) 
    Missing                                      128 (11.7)                     7 (12.5) 
Initial CNS score                                                                                             0.67
     CNS-1                                         1028 (93.6)                    54 (96.4)
     CNS-2/TLP+                                50 (4.6)                         1 (1.8)
     CNS-3                                            16 (1.5)                         0 (0.0)
    Missing                                         4 (0.4)                         1 (1.8)
WBC: white blood cell; NCI: National Cancer Institute; MRD: minimal residual disease;
CNS: central nervous system; TLP: traumatic lumbar puncture.
Table 2. Frequency of CD200/BTLA deletions according to BCP-ALL
genetic subtypes and genetic risk groups.
                                      Not deleted (n=1098)   Deleted (n=56)   P value
                                                  N. (%)                       N. (%)                
Genetic subtypes                                                                                           <0.0001 
     ERGdel                                             36 (3.3)                         1 (1.8)                   
     ETV6-RUNX1                              248 (22.6)                     34 (60.7)                 
     High hyperdiploidy                  382 (34.8)                       4 (7.1)                   
     BCR-ABL1                                     24 (2.2)                         3 (5.4)                   
     Low hypo/near-haploidy            9 (0.8)                          1 (1.8)                   
     MLL translocation                      17 (1.5)                         0 (0.0)                   
     iAMP21                                          21 (1.9)                         4 (7.1)                   
     TCF3-PBX1                                   47 (4.3)                         0 (0.0)                   
     B-other                                       314 (28.6)                      9 (16.1)                  
IKZF1del                                            172 (15.7)                     10 (17.9)               0.7
Genetic groups *                                                                                              0.004
     Good-prognosis                       666 (60.7)                     39 (69.6)                 
     Intermediate-prognosis         361 (32.9)                      9 (16.1)                  
    Poor-prognosis                           71 (6.5)                        8 (14.3)                  
Genetic risk groups were defined as follows: good-prognosis group includes all patients
with high hyperdiploidy, ETV6-RUNX1 or ERGdel; intermediate-prognosis group includes
patients with TCF3-PBX1 and B-other patients; poor-prognosis group includes all
patients with MLL translocation, BCR-ABL, low hypodiploidy/near-haploidy or iAMP21.
deletions tended towards a worse 8-year event-free sur-
vival rate (HR 1.80; 99% CI 0.57-5.70; P=0.18) while over-
all survival was barely influenced (HR 1.02; 99% CI 0.15-
7.03; P=0.97) (Online Supplementary Figure S1C). Notably,
in the intermediate-prognosis genetic group, CD200/BTLA
deletions were significantly associated with an inferior 8-
year event-free survival [33.3% (95% CI 7.8-62.3) versus
76.2% (95% CI 71.0-80.6); HR 4.00 (99% CI 1.34-11.93);
P<0.001] and an inferior 8-year overall survival [48.6%
(95% CI 12.8-77.6) versus 86.9% (95%CI 82.6-90.2); HR
4.43 (99%CI 1.15-17.03); P=0.002] (Figure 4A,B). No sig-
nificant differences in leukemic and clinical characteristics
were observed between patients with and without
CD200/BTLA deletions in the intermediate-prognosis
genetic group (Online Supplementary Table S5). In the inter-
mediate-prognosis genetic group, comparing the patients
with and without CD200/BLTA deletions, the former had
higher incidences of not achieving complete remission
(2/9 versus 7/361) and of relapsing (4/9 versus 67/361). Both
children with CD200/BTLA deletions who failed to
achieve complete remission died during induction, one
from sepsis and the other from necrotising enterocolitis. A
similar failure to achieve complete remission was
observed in three patients in the non-deleted group.
Within the intermediate-prognosis genetic group the dis-
ease-free survival rates of patients with and without
CD200/BTLA deletions were 42.9% versus 77.7%, respec-
tively (HR 3.03; 99% CI 0.81-11.41; P=0.02). 
Finally, multivariate analysis was performed to evaluate
the prognostic role of CD200/BTLA deletions after adjust-
ing for conventional risk criteria (Table 4). In the whole
cohort, CD200/BTLA deletions were independently asso-
ciated with inferior 8-year event-free survival (HR 1.97;
95% CI 1.17-3.32; P=0.01) and disease-free survival (HR
1.83; 95% CI 1.05-3.18; P=0.03) as shown in a Cox regres-
sion model including gender, IKZF1 status, response to
pre-phase and genetic risk groups.
The inferior event-free survival was confirmed for the
CD200/BTLA-deleted patients in the intermediate-progno-
sis genetic group (HR 2.99; 95% CI 0.97-9.31; P=0.01),
whereas disease-free survival was comparable with that of
the patients without CD200/BTLA deletions (HR 2.11;
99% CI 0.54-8.29; P=0.16).
Discussion
Genomic profiling studies have uncovered a plethora of
genomic lesions involved in the pathogenesis of BCP-
ALL.21 Notably, some of these genetic alterations are clini-
cally relevant and might be included in future stratification
strategies for the treatment of pediatric BCP-ALL. Of par-
ticular interest, IKZF1 alterations have been found in
BCR–ABL-positive12,22 and in a small fraction of BCR–ABL-
negative23 BCP-ALL and have shown predictive value for
F. Ghazavi et al.
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Figure 3. Associations between CD200/BTLA deletions and outcome
of all BCP-ALL patients treated according to the EORTC 58951 trial.
Kaplan-Meier curves of (A) event-free survival, (B) disease-free sur-
vival and (C) overall survival in all BCP-ALL patients according to the
presence of CD200/BTLA deletions.
Table 3. An overview of event status and relapse types in BCP-ALL
patients.
Not deleted n=1098 Deleted n=56
Characteristic N. (%) N. (%)
No CR+ induction death                    12 (1.1)                            2 (3.6)
Relapse:                                               143 (13.0)                       14 (25.0)
BM                                                                96 (8.7)                            10 (17.9)
CNS                                                              10 (0.9)                             1 (1.8)
Other isolated                                             8 (0.7)                                0 (0)
BM+CNS                                                     15 (1.4)                             3 (5.4)
BM+other                                                   13 (1.2)                                0 (0)
Unknown                                                       1 (0.1)                                0 (0)
Treatment-related mortality             13 (1.2)                             1 (1.8)
Continued complete remission     930 (84.7)                       39 (69.9)
Survival status:                                                                                       
Alive                                                   1012 (92.2)                        49 (87.5)
Dead                                                     86 (7.8)                            7 (12.5)
CR: complete remission; BM: bone marrow; CNS: central nervous system.
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poor treatment outcome in several studies.2,11,16,24,25 In con-
trast, ERG deletions were shown to be associated with
good treatment response.3,13 In addition, Clappier and col-
leagues showed that the presence of IKZF1 deletions
failed to influence the good treatment outcome generally
observed in ERG-deleted BCP-ALL patients.3 All together,
these results suggest that in-depth genomic profiling of
primary BCP-ALL is clinically important and can provide
new opportunities for further improvement of BCP-ALL
risk stratification. 
In this study, we characterized a recurrent somatic dele-
tion of approximately 164 kb at the 3q13.2 locus. This
deletion targets BTLA and CD200 and occurred in 10% of
our initial cohort (7 out of 70) and in 4.85% of our extend-
ed validation cohort (56 out of 1154). CD200/BTLA dele-
tions have been previously reported in independent
genome-wide copy number profiling studies in BCP-
ALL.2,14-18 Importantly, both BTLA and CD200 encode lym-
phoid signaling molecules with putative functions in B-cell
receptor and MAPK/PI3K signaling, both of which are
essential for B-cell proliferation and maturation.26,27 A high
frequency of focal CD200/BTLA deletions in combination
with the lack of somatic mutations targeting these genes,
suggests that combined loss of both lymphoid signaling
molecules might be required during leukemogenesis.
Alternatively, the deletion of both genes might be required
because of the presence of a RAG signal sequence and
thus might represent an epiphenomenon of another event
in the process of leukemogenesis. In vivo experiments will
enable the assessment of the validity of these hypotheses.
CD200/BTLA deletions clearly affected CD200 expres-
sion levels in B-ALL cell lines and in patients with primary
BCP-ALL. Moreover and in line with the variable pattern
of CD200 expression that has been reported in B and T
cells,28 BCP-ALL patients and B-ALL cell lines that lacked
CD200/BTLA deletions were also characterized by a vari-
able range of CD200 expression levels. Notably, low or
absent CD200 expression in these CD200/BTLA-deletion-
negative BCP-ALL patients and cell lines suggests that
alternative mechanisms, such as epigenetic silencing,
might be implicated in CD200 inactivation.29 In contrast,
the levels of BTLA (CD272) were generally low in all cell
lines and BCP-ALL patients’ samples analyzed, which cor-
responds to the marginal levels of BTLA detected in pro,
pre and immature B cells.26 All together, these expression
data seem to suggest that BTLA only plays a marginal role
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Table 4. Multivariate analysis of outcome in BCP-ALL patients enrolled in the EORTC-CLG 58951 trial.
Event-free survival Disease-free survival Overall survival
The whole cohort of patients HR 95% CI P HR 95% CI P HR 95% CI P
CD200/BTLA Status Deleted vs. non-deleted 1.98 1.18-3.32 0.01 1.84 1.06-3.19 0.03 1.73 0.79-3.78 0.17
IKZF1 status Deleted vs. non-deleted 1.63 1.17-2.28 0.004 1.63 1.15-2.32 0.006 1.01 0.61-1.66 0.98
Gender Male vs. female 1.67 1.24-2.27 <.001 1.80 1.31-2.47 <.001 1.18 0.78-1.78 0.44
Response to prephase ≥ vs. <1000 blasts/μL 1.58 1.02-2.46 0.04 1.16 0.70-1.94 0.57 2.00 1.13-3.53 0.02
Genetic status Intermediate vs. good prognosis 2.36 1.68-3.31 <.001 2.35 1.65-3.34 <.001 3.21 1.95-5.28 <.001
Genetic status Poor vs. good prognosis 4.96 3.17-7.75 <.001 5.59 3.55-8.82 <.001 6.35 3.36-12.01 <.001
The intermediate-prognosis genetic group HR 99% CI P HR 99% CI P HR 99% CI P
CD200/BTLA status Deleted vs. non-deleted 3.00 0.97-9.31 0.01 2.11 0.54-8.29 0.16 4.31 1.06-17.54 0.007
IKZF1 status Deleted vs. non-deleted 1.94 1.05-3.59 0.005 2.05 1.07-3.90 0.004 1.19 0.50-2.82 0.61
Gender Male vs. female 2.07 1.14-3.74 0.002 2.36 1.25-4.47 <.001 1.77 0.82-3.83 0.06
Response to prephase ≥ vs. <1000 blasts/μL 1.49 0.68-3.29 0.19 0.97 0.36-2.56 0.93 1.40 0.48-4.08 0.42
Figure 4. Associations between CD200/BTLA deletions and outcome in the intermediate-prognosis genetic risk group of BCP-ALL patients
treated according to the EORTC 58951 trial. Kaplan-Meier curves of (A) event-free survival and (B) overall survival in the intermediate-progno-
sis genetic group according to the presence of CD200/BTLA deletions.
A B
in BCP-ALL disease pathology and that CD200 might rep-
resent the main functionally relevant target for this partic-
ular deletion.
Mapping of the exact genomic breakpoints of
CD200/BTLA deletions in BCP-ALL suggests aberrant
RAG-mediated recombination as the mechanism under-
lying this genetic alteration. Notably, a similar RAG
“footprint” pattern was previously observed for recurring
copy number alterations in BCP-ALL such as PAX5,
CDKN2A, BTG1, RAG1, RAG2, IKZF2 and IKZF3, ERG,
C20orf94.9,30
In our study, we observed an association of
CD200/BTLA deletions with inferior 8-year event-free sur-
vival (HR 2.02; 95% CI 1.23-3.32; P=0.005) and disease-
free survival (HR 1.92; 95% CI 1.13-3.26; P=0.014) in BCP-
ALL patients treated according to the EORTC-CLG 58951
protocol. Multivariate analysis confirmed the independent
prognostic value of the CD200/BTLA deletions in the
whole cohort of BCP-ALL patients.  The lack of impact on
overall survival indicates that relapsing patients can be res-
cued by second-line therapy. However, considering the
increase in toxicity and late effects with increasing
chemotherapy doses and the fact that many relapsing
patients will eventually undergo hematopoietic stem cell
transplantation, prevention of relapse by precise risk strat-
ification remains an important issue. The timing of relaps-
es (at/after the end of therapy) observed in this study, as
well as the chemosensitivity to second-line rescue treat-
ment, suggests that intensification of frontline treatment
might prevent some of the relapses. Whether this should
be achieved by treating patients at risk according to a
high-risk schedule or by introducing less intensive modifi-
cations for instance during maintenance treatment, cannot
be concluded yet. 
CD200/BTLA deletions were most prevalent in the poor-
prognosis genetic group (8/79=10.1%), but the highest
number of CD200/BTLA-deleted cases was detected in the
good-prognosis genetic group in which a strong associa-
tion of CD200/BTLA deletions with ETV6-RUNX1-posi-
tive leukemias was observed (34 out of 56 deleted cases,
P<0.0001). Notably, these findings further extend the
causal role of aberrant RAG recombinase activity in the
generation of cooperative genomic lesions that eventually
lead to full leukemic transformation in ETV6-RUNX1
ALL.31 Moreover, the excellent clinical outcome of ETV6-
RUNX1 patients was not affected by the presence of
CD200/BTLA deletions in this good-prognosis genetic sub-
type of BCP-ALL (Online Supplementary Figure S2). In con-
trast, although based on a small number of events, the
presence of CD200/BTLA deletions in BCP-ALL patients
within the intermediate-prognosis genetic group (9 out of
370) was associated with an inferior outcome.
In 2009, Mullighan and colleagues assessed the prognos-
tic relevance of IKZF1 alterations, EBF1 and CD200/BTLA
deletions in two independent cohorts with different sam-
ple composition and treatment schedules.2 In the test
cohort, all three genetic lesions were significantly associat-
ed with poor treatment outcome. However, this associa-
tion could only be confirmed for IKZF1 alterations in a val-
idation series. Notably, the sample composition of the test
and validation cohorts in this study was markedly differ-
ent. In the test cohort, only three out of 221 BCP-ALL
patients were positive for ETV6-RUNX1, whereas the
majority of the patients could be allocated to the interme-
diate-prognosis genetic group due to the presence of the
TCF3-PBX1 translocation (25 out of 221) or the lack of any
other known genetic prognostic marker (149 out of 221).
Importantly, the sample distribution of the validation
cohort was completely different, with ETV6-RUNX1-pos-
itive patients accounting for 19.3% (50 out of 258) of this
cohort and only 34.5% (89 out of 258) being in the inter-
mediate-prognosis genetic group. Given the strong link of
CD200/BTLA deletions with prognostically favorable
ETV6-RUNX1 alterations and the association of
CD200/BTLA deletions with poor outcome in the interme-
diate genetic risk group (this study), these differences in
sample distribution might explain why the prognostic
impact of CD200/BTLA deletions was not validated in this
particular study.2
Overall, our study confirms that CD200/BTLA deletions
are recurrent genetic lesions in the biology of BCP-ALL
and identifies their exact frequency in a large and uniform-
ly treated population of patients with BCP-ALL.
CD200/BTLA deletions are highly enriched in ETV6-
RUNX1-positive leukemias, suggesting a genetic interac-
tion between these genomic alterations in the pathogene-
sis of BCP-ALL. Finally, our study demonstrates a prognos-
tic value of CD200/BTLA deletions, probably restricted to
a specific subgroup of BCP-ALL patients, and validates the
previous association between CD200/BTLA deletions and
poor clinical outcome in BCP-ALL.2 CD200/BTLA dele-
tions are not currently included in novel genetic risk clas-
sification algorithms in BCP-ALL, such as the one recently
introduced by Moorman and colleagues.32 However, our
data suggest that CD200/BTLA deletions have potential
value to be added to this algorithm, which is built by inte-
grating data on copy number alterations from eight key
genes/loci (BTG1, PAX5, CDKN2A/B, IKZF1, ETV6, RB1,
PAR1, EBF1) with established cytogenetic risk groups.32
Nevertheless, additional studies are mandatory to under-
stand the exact role of CD200/BTLA deletions in malig-
nant precursor B-cell transformation and their effects on
treatment response. 
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